

## Index to Public Law Correspondence

1. Dear Manufacturer Letter dated **November 20, 1992**, annual guidance.
2. Dear Manufacturer Letter dated **December 30, 1992**, regarding request for increase to the FCP.
3. Dear Radiopharmacy Operator Letter dated **February 3, 1993**, regarding in vivo diagnostics and Radiopharmacy Manufacturers.
4. Dear Manufacturer Letter dated **February 24, 1993**, regarding request for increase to the FCP (See also Dear Manufacturer Letter dated December 30, 1992).
5. Assistant General Counsel letter to DAS for A&MM dated **March 29, 1993**, regarding Impact of Public Law 102-585 on FSS Contract Pricing.
6. Dear Radiopharmaceutical Industry Member Letter dated **April 16, 1993**, regarding agreement between the Department and manufacturers that Radiopharmacies will not be considered wholesalers.
7. Dear Member of the I.V. Solutions Industry Letter dated **April 22, 1993**, regarding the covered status of I.V. Solutions.
8. Dear Manufacturer Letter dated **May 4, 1993**, regarding technical amendment to the P.L. (dual pricing).
9. OGC Letter dated **May 27, 1993**, regarding transfer of covered drugs (see also Dear Manufacturer Letter dated October 15, 1997).
10. Dear Manufacturer Letter dated **June 4, 1993**, regarding sales from “any State or Territory of the United States, the District of Columbia, and the Commonwealth of Puerto Rico”.
11. General Counsel Letter dated **July 15, 1993**, regarding delegation of Hearing Responsibility, establishing the Nominal Increase Board and its authority to rule on requests for nominal increases in FCP(s).
12. Dear Manufacturer Letter dated **September 23, 1993**, regarding additions of new covered drugs.
13. Dear Manufacturer Letter dated **October 19, 1993**, annual guidance.

14. Dear I.V. Solution Manufacturer Letter dated **October 29, 1993**, regarding covered drug status of certain I.V. Solutions.
15. Dear Manufacturer Letter dated **September 1, 1994**, annual guidance.
16. Dear Manufacturer Letter dated **September 25, 1995**, annual guidance.
17. Dear Manufacturer Letter dated **September 25, 1995**, regarding common errors observed by OIG in the computation of non-FAMPs and FCPs.
18. Dear Manufacturer Letter dated **October 7, 1996**, supplemental guidance regarding nominal prices, drug samples, and TRICARE.
19. Dear Manufacturer Letter dated **October 16, 1996**, annual guidance.
20. Dear Manufacturer Letter dated **February 11, 1997**, regarding penny prices for single price list companies.
21. Dear Manufacturer Letter dated **October 15, 1997**, regarding record retention, 2-step computation, transferring covered drugs from one manufacturer to another, and custom or private label packaging (common calculation errors and compliance issues).
22. Dear Manufacturer Letter dated **October 16, 1997**, annual guidance.
23. Letter from Pharmacia and Upjohn dated **October 27, 1997**, regarding private label packaging (presenting four hypothetical private label scenarios to for VA guidance).
24. Response to Pharmacia Letter dated **November 21, 2007**.
25. Office of General Counsel Letter dated **May 8, 1998**, regarding calculation of FCPs for Flu Vaccines.
26. Dear Manufacturer Letter dated **October 16, 1998**, annual guidance.
27. Dear Manufacturer Letter dated **October 18, 1999**, regarding common calculation errors and compliance issues and providing Manufacturers with all previous PL guidance.
28. Dear Manufacturer Letter dated **October 19, 1999**, annual guidance.

29. Dear Manufacturer Letter dated **October 18, 2000**, annual guidance.
30. Dear Manufacturer Letter dated **October 19, 2001**, annual guidance.
31. Dear Manufacturer Letter dated **October 19, 2001**, regarding who is a manufacturer under licensing agreements, guidance on certain purchases by INS, exclusion of sales to § 602 entities at less than the statutory price through their PPV's, and calculation of new covered drug pricing (common calculation errors and compliance issues).
32. Dear Manufacturer Letter dated **October 18, 2002**, regarding sub-340B-ceiling wholesaler sales and the non-FAMP.
33. Dear Manufacturer Letter dated **October 18, 2002**, annual guidance.
34. Dear Manufacturer Letter dated **October 16, 2003**, annual guidance.
35. Dear Manufacturer Letter dated **March 31, 2004**, regarding flu vaccines (See also Dear Manufacturer Letter dated May 8, 1998).
36. Dear Manufacturer Letter dated **July 8, 2004**, regarding certain sales of inpatient covered drugs to DSHs participating in PHS's 340B program and the non-FAMP calculation.
37. Dear Manufacturer Letter dated **October 14, 2004**, regarding non-FAMP calculations and TRRx sales.
38. Dear Manufacturer Letter dated **October 14, 2004**, regarding Public Law and TRICARE.
39. Dear Manufacturer Letter dated **October 19, 2004**, annual guidance.
40. Dear Manufacturer Letter dated **October 14, 2005**, annual guidance.
41. Dear Manufacturer Letter dated **October 18, 2006**, annual guidance.
42. Dear Manufacturer Letter dated **October 18, 2006**, FAQs regarding non-FAMPs.
43. Dear Manufacturer Letter dated **October 22, 2007**, annual guidance.

44. Dear Manufacturer Letter dated **October 26, 2007**, FAQs regarding non-FAMPs and FCPs.
45. Dear Manufacturer Letter dated **October 22, 2008**, annual guidance.
46. Dear Manufacturer Letter dated **October 16, 2009**, annual guidance.
47. Dear Manufacturer Letter dated **October 19, 2010**, regarding guidance on adding new covered drugs and new package sizes of existing covered drugs to FSS contracts.
48. Dear Manufacturer Letter dated **October 19, 2010**, annual guidance.
49. NAC Letter dated **November 3, 2010**, request for modification package submission and Pharmaceutical Pricing Agreement Addendum A.
50. PBM Dear Manufacturer Letter dated **October 19, 2011**, annual guidance.
51. OGC Dear Manufacturer Letter dated **November 2, 2011**, new package size FCPs.
52. NAC Letter dated **November 4, 2011**, request for modification package submission and Pharmaceutical Pricing Agreement Addendum A.
53. PBM Dear Manufacturer Letter dated **October 16, 2012**, annual guidance.
54. OGC Dear Manufacturer Letter dated **September 25, 2012**, annual guidance.
55. NAC Letter dated **November 4, 2012**, request for modification package and Pharmaceutical Pricing Agreement Addendum A.